Xylem price target raised to $152 from $147 at Oppenheimer

Oppenheimer raised the firm’s price target on Xylem to $152 from $147 and keeps an Outperform rating on the shares. The firm came away from Xylem’s 2024 Investor Day incrementally confident in New Xylem’s differentiated competitive position and prospects for compound earnings growth over the coming years, the analyst tells investors in a research note. The firm believes medium-term financial targets highlighted by mid-teens EPS CAGR may ultimately prove conservative.